Share on StockTwits

Analysts at Piper Jaffray dropped their target price on shares of Amedisys (NASDAQ:AMED) from $13.00 to $12.00 in a research report issued to clients and investors on Monday, reports. Piper Jaffray’s target price would indicate a potential downside of 19.08% from the company’s current price.

In other Amedisys news, major shareholder North Tide Capital, Llc acquired 500,000 shares of Amedisys stock on the open market in a transaction dated Thursday, May 8th. The stock was purchased at an average price of $13.90 per share, for a total transaction of $6,950,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Large shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

A number of other firms have also recently commented on AMED. Analysts at Zacks reiterated a “neutral” rating on shares of Amedisys in a research note on Thursday, March 27th. They now have a $15.00 price target on the stock. Separately, analysts at Credit Suisse cut their price target on shares of Amedisys from $10.00 to $9.00 in a research note on Thursday, March 13th. Finally, analysts at Oppenheimer downgraded shares of Amedisys from an “outperform” rating to a “market perform” rating in a research note on Tuesday, March 11th. They now have a $16.00 price target on the stock. Four analysts have rated the stock with a sell rating, three have assigned a hold rating and one has issued a buy rating to the stock. Amedisys presently has an average rating of “Hold” and an average target price of $11.14.

Amedisys (NASDAQ:AMED) traded down 0.94% during mid-day trading on Monday, hitting $14.83. The stock had a trading volume of 409,438 shares. Amedisys has a 1-year low of $9.51 and a 1-year high of $18.70. The stock’s 50-day moving average is $14.13 and its 200-day moving average is $15.08. The company’s market cap is $483.6 million.

Amedisys (NASDAQ:AMED) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.07) earnings per share for the quarter, missing the analysts’ consensus estimate of $0.56 by $0.63. The company had revenue of $298.74 million for the quarter, compared to the consensus estimate of $301.89 million. During the same quarter last year, the company posted $0.13 earnings per share. Amedisys’s revenue was down 9.1% compared to the same quarter last year. Analysts expect that Amedisys will post $0.05 EPS for the current fiscal year.

Amedisys, Inc (NASDAQ:AMED) is a health care company focused on bringing home the continuum of care.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.